Lefamulin最初由Nabriva开发,2018年3月仑胜医药获得在大中华区,包括中国大陆、香港、澳门、台湾开...查看全文
$Nabriva Therapeutics(NBRV)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2019-07-01 AccNo: 0001193125-19-187447 Size: 45 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 8-K - Current report Filed: 2019-06-25 AccNo: 0001104659-19-037436 Size: 353 KBItem 1.01: Entry into a Material Definitive AgreementItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接
$Nabriva Therapeutics(NBRV)$ 424B5 - Prospectus [Rule 424(b)(5)] Filed: 2019-06-25 AccNo: 0001047469-19-003866 Size: 532 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 8-K - Current report Filed: 2019-06-20 AccNo: 0001104659-19-036587 Size: 48 KBItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接
$Nabriva Therapeutics(NBRV)$ DEF 14A - Other definitive proxy statements Filed: 2019-06-14 AccNo: 0001047469-19-003649 Size: 755 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2019-05-10 AccNo: 0001104659-19-028565 Size: 6 MB 网页链接
$Nabriva Therapeutics(NBRV)$ 8-K - Current report Filed: 2019-05-10 AccNo: 0001104659-19-028448 Size: 160 KBItem 2.02: Results of Operations and Financial ConditionItem 9.01: Financial Statements and Exhibits 网页链接
$Nabriva Therapeutics(NBRV)$ 8-K - Current report Filed: 2019-05-01 AccNo: 0001104659-19-025701 Size: 42 KBItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接
$Nabriva Therapeutics(NBRV)$ 8-K - Current report Filed: 2019-04-01 AccNo: 0001104659-19-018855 Size: 24 KBItem 8.01: Other Events 网页链接